Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study (Q33391580)

26 July 2017

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study (English)

1 reference

chronic immune thrombocytopenia

26 July 2017

1 reference

1 reference

9

James B Bussel

1 reference

26 July 2017

Gregory Cheng

1

1 reference

26 July 2017

Mansoor N Saleh

2

1 reference

26 July 2017

Claus Marcher

3

1 reference

26 July 2017

Sandra Vasey

4

1 reference

26 July 2017

Bhabita Mayer

5

1 reference

26 July 2017

Manuel Aivado

6

1 reference

26 July 2017

Michael Arning

7

1 reference

26 July 2017

Nicole L Stone

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

26 July 2017

1 reference

26 July 2017

377

1 reference

26 July 2017

9763

1 reference

26 July 2017

393-402

1 reference

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Current options for the treatment of idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

The pathogenesis of immune thrombocytopaenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

How I treat idiopathic thrombocytopenic purpura (ITP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy--thrombocytopenia (FACT-Th) questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

The development and psychometric evaluation of the Motivation and Energy Inventory (MEI).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Treatment of chronic immune thrombocytopenic purpura: the patients' perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Morbidity and mortality in adults with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Management of patients with refractory immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

Refractory immune thrombocytopenic purpura: current strategies for investigation and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960959-2

7 January 2021

10.1016/S0140-6736(10)60959-2

Identifiers

DOI

1 reference

26 July 2017

1 reference